Skip to main content

Collaboration opportunities with Daiichi Sankyo in early stage research and technology

      Daiichi Sankyo, the global pharmaceutical company with corporate origins in Japan is seeking research collaborations with UK entities in a number of key areas.

      Book online

      One Nucleus is delighted to be working with Daiichi Sankyo and the Department for International Trade Japan Team to bring you a free online seminar to enable you to learn about the Daiichi Sankyo research priorities and collaboration structures available. The core areas of interest include:

      • Novel modality technologies in oncology and CNS (psychiatric and neurodegenerative disease)
      • Novel drug delivery technologies to cancer cells or brain after systemic administration
      • Novel target or cancer-specific antigen for antibody in oncology

      Programme:

      10.00 – Collaboration Opportunities with Daiichi Sankyo in Early Stage Research and Technology
      Kunihiko Fujii, Manager, BD & Licensing, Daiichi Sankyo

      10.45 – Q&A

      11.00 – Close

      Registration is free and the limited places will be allocated on a first-come-first-served basis.

      Please note, all registrations are subject to the approval of the sponsor.  You will be informed if your registration has been unsuccessful within 2 working days of registering online for the event.

      For more information, please contact [email protected]

      Contact us
      =